chartexchange

Clearmind Medicine Among Top Biopharma Companies Invited to join Washington DC, Psychedelic Summit

GlobeNewswire Inc. | Nov 10, 2026 7:32 AM EST

Vancouver, Canada, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogens for scalable treatment  of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (“AUD”),  today announced that it is among the invitees to join researchers, clinicians, federal agency representatives, and policymakers at the Frontiers of Mental Health and Recovery Summit being held this week in Washington D.C.. Convened by BrainFutures with the support of the Steven & Alexandra Cohen Foundation , Clearmind's Chief of Global Impact, Mary-Elizabeth Gifford , has been asked to join what BrainFutures describes as "a select group of leaders shaping the future of mental health care," through hands-on participation in two days of "collaborative working sessions" to begin to tackle the question of how to "accelerate system readiness for psychedelic therapies." "Our approach at Clearmind Medicine is to support 'system readiness' to advance a next-generation, psychedelic-derived neuroplastogen treatment model that could potentially reduce the need for lengthy and costly supervised dosing," said Gifford.

Read original article